At the Centro di riferimento per la diagnosi e la cura dell’orbitopatia basedowiana of the Policlinico di Milano, a 52-year-old male patient with rapidly progressing thyroid eye disease received the first-approved targeted biologic therapy in Italy, marking a significant milestone for managing severe autoimmune ophthalmopathy.
In Plain English: The Clinical Takeaway
- Targeted Biologic Action: The new therapy, a monoclonal antibody called teprotumumab, acts directly on the mechanisms of the disease, reducing inflammation as well as eye bulging and double vision.
- Preserving Vision: The treatment is designed to actively reduce eye bulging (exophthalmos) and double vision (diplopia), rather than just masking surface inflammation.
- Specialized Access: Currently, infusions are restricted to authorized reference centers for carefully evaluated cases while national reimbursement pathways are finalized.
Understanding the Pathophysiology of Thyroid Eye Disease
Thyroid Eye Disease (TED), clinically referred to as Basedowian orbitopathy, is an autoimmune condition often associated with Basedow’s disease, an autoimmune pathology affecting the thyroid that causes hyperthyroidism. In this pathology, the immune system attacks the ocular muscles and the fat around the eyes. This autoimmune attack triggers inflammation, leading to the expansion of orbital tissues. As the muscles and fat swell, the globe is pushed forward, resulting in characteristic proptosis, or exophthalmos.
Beyond the physical disfigurement, patients can suffer from functional impairments, including double vision (diplopia) and, in the most severe cases, permanent damage to vision. Historical management strategies relied heavily on corticosteroids. While corticosteroids are effective in controlling inflammation, they are less effective against the most disabling manifestations of the disease, such as exophthalmos and diplopia. Consequently, patients with advanced disease often required orbital surgery.
The Mechanism of Action of Teprotumumab
The newly administered therapy at the Policlinico di Milano utilizes teprotumumab, a monoclonal antibody of the latest generation. This drug acts directly on the mechanisms of the disease, reducing inflammation, eye bulging, and double vision.
Patients undergo a regimen consisting of eight intravenous infusions administered once every three weeks. This targeted approach aims to intervene not only on inflammation but also on the manifestations that have the greatest impact on visual function and quality of life, potentially reducing the need for surgical interventions.
| Parameter | Traditional Corticosteroids | Teprotumumab (Monoclonal Antibody) |
|---|---|---|
| Target Mechanism | Effective primarily in the control of inflammation | Acts directly on the mechanisms of the disease |
| Primary Efficacy | Effective in acute inflammation | Reduces inflammation, structural proptosis, and diplopia |
| Administration | Not specified | Intravenous infusion every 3 weeks (8-dose cycle) |
| Surgical Need | Often required for severe exophthalmos and diplopia | May reduce the need for orbital surgery |
Multidisciplinary Integration and Regional Healthcare Access
The administration of this therapy at the Milan facility highlights the critical role of coordinated, multidisciplinary care models in managing complex autoimmune diseases. The institutional center, which follows approximately 600 patients annually, integrates endocrinologists, ophthalmologists, otorhinolaryngologists, orbital surgeons, radiologists, and hospital pharmacists. This collaborative network ensures patient selection adheres to criteria established by AIFA, pending the definition of the reimbursement pathway.
Contraindications & When to Consult a Doctor
Early identification remains critical for optimizing therapeutic outcomes and preserving visual function.
References
- ticinonotizie.it
- lamilano.it
- AIFA (Agenzia Italiana del Farmaco)
